Effect of ABO blood type on the outcomes of patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors.

摘要: Abstract Objectives To assess the effect of blood type on survival outcomes and adverse events (AEs) in patients treated with tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC). Materials methods Patients who received TKIs as first-line therapy mRCC between 2008 2015 at our hospital were included study ( n = 136). divided into 2 groups based their O non-O. Survival AEs compared according to type. Cox regression models used univariate multivariate analyses. Results Of 136 patients, 34 (25%) 102 (75%) had non-O types, respectively. Blood was associated an increased number disease sites. There no differences respect other baseline characteristics. The progression-free types 12.1 11.6 months, respectively; overall 34.4 24.8 On analyses, ABO not a significant prognostic factor or survival. Furthermore, incidences serious similar groups. Conclusions TKIs. However, may be